PRX-102 ERT Improves Kidney Function in Patients Treated With Replagal, Trial Shows
Treatment with PRX-102 (pegunigalsidase alfa), Protalix BioTherapeutics’ investigational enzyme replacement therapy (ERT) for Fabry disease, led to significant improvements in kidney function in patients who had been previously treated with Replagal, according to top-line data from the BRIDGE Phase 3 trial. PRX-102 is a man-made…